SUZHOU, China, April 15, 2025 /PRNewswire/ --In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted ...

KYOTO—Researchers have safely transplanted nerve cells generated from induced pluripotent stem (iPS) cells into the brains of ...

Two early-phase clinical trials demonstrate the safety and potential clinical utility of stem cell therapies to ease motor ...

Professor Kenji Osafune (Department of Cell Growth and Differentiation) and his team of researchers have devised an effective ...

differentiation of iPS cells into relevant cell types in vitro for transplantation, and removal of contaminating stem or progenitor cells before transplantation. Study of abnormal phenotypes ...

Induced neural progenitor cells (iNPCs), derived from induced pluripotent stem cells (iPSCs), are a relatively new method for modeling the cellular interactivity, biochemical alterations, and ...

More information: Aaron Stahl et al, Patient iPSC-derived neural progenitor cells display aberrant cell cycle control, p53, and DNA damage response protein expression in schizophrenia, BMC ...

Additionally, XellSmart's allogeneic, off-the-shelf iPSC-derived dopaminergic neural progenitor cell injection ("XS-411 Injection") has also been approved by China's National Medical Products ...

XellSmart has successfully achieved large-scale manufacturing of multiple GMP-grade iPSC-derived neural progenitor cell therapies. XellSmart's allogeneic iPSC-derived cell therapies, XS411 and XS228, ...

The approval of XellSmart's clinical trial, along with the special exemption granted, signifies the FDA's recognition of XellSmart's well-established clinical-grade iPSC-derived cell drug development, ...